Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 07 2023
28 07 2023
Historique:
received:
06
04
2023
accepted:
25
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.
Identifiants
pubmed: 37507480
doi: 10.1038/s41598-023-39386-x
pii: 10.1038/s41598-023-39386-x
pmc: PMC10382472
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
12255Informations de copyright
© 2023. The Author(s).
Références
Curr Cancer Drug Targets. 2007 Sep;7(6):566-81
pubmed: 17896922
Breast. 2019 Dec;48:7-16
pubmed: 31470257
Breast Cancer Res Treat. 2015 Jan;149(1):199-209
pubmed: 25472915
J Clin Invest. 2000 Apr;105(8):1045-7
pubmed: 10772648
Clin Breast Cancer. 2021 Aug;21(4):302-308
pubmed: 33750642
Lancet Oncol. 2012 Apr;13(4):e148-60
pubmed: 22469125
PLoS One. 2017 Mar 15;12(3):e0173693
pubmed: 28296916
J Pharmacol Pharmacother. 2014 Jul;5(3):186-92
pubmed: 25210398
Clin Breast Cancer. 2010 Aug 1;10(4):301-6
pubmed: 20705563
Surg Clin North Am. 2018 Aug;98(4):819-833
pubmed: 30005776
BMC Cancer. 2019 Nov 12;19(1):1091
pubmed: 31718602
J Clin Oncol. 2006 Aug 1;24(22):3623-8
pubmed: 16877730
J Geriatr Oncol. 2014 Jul;5(3):252-9
pubmed: 24661770
Lancet Oncol. 2007 Dec;8(12):1101-1115
pubmed: 18054880
Nihon Ronen Igakkai Zasshi. 2006 Jan;43(1):27-34
pubmed: 16521795
Tumori. 2017 Jan 21;103(1):e4-e8
pubmed: 27647223
J Clin Oncol. 1999 Feb;17(2):485-93
pubmed: 10080589
Breast J. 2020 Mar;26(3):433-439
pubmed: 31538705
J Breast Cancer. 2017 Dec;20(4):368-377
pubmed: 29285042
Oncology. 2007;73(3-4):228-37
pubmed: 18424887
Breast Cancer Res Treat. 2016 Dec;160(3):501-509
pubmed: 27752847
Cancer Chemother Pharmacol. 2012 Feb;69(2):515-22
pubmed: 21874317
Blood. 2005 Apr 1;105(7):2862-8
pubmed: 15591121
Cancer Treat Rev. 2011 Dec;37(8):590-8
pubmed: 21592672
Cancer. 2015 Sep 1;121(17):2984-92
pubmed: 26033177
Tumori. 2015 Jan-Feb;101(1):30-5
pubmed: 25702645
Lancet Healthy Longev. 2021 Oct;2(10):e663-e677
pubmed: 36098020
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Clin Breast Cancer. 2020 Jun;20(3):e315-e326
pubmed: 32273207
Adv Ther. 2019 Feb;36(2):381-406
pubmed: 30565179
Invest New Drugs. 2017 Jun;35(3):359-374
pubmed: 27909934
Breast Cancer Res Treat. 2021 Dec;190(3):415-424
pubmed: 34546500
Breast Care (Basel). 2018 Jul;13(3):177-181
pubmed: 30069178
Cancer Lett. 2015 Mar 28;358(2):100-106
pubmed: 25541061